Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC.
Company Details
- Employees
- 129
- Address
- 10275 Science Center Dr,
- Phone
- 212-433-3791
- in****@****lis.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- zentalis.com
- HQ
- San Diego, California
Zentalis Pharmaceuticals Questions
Zentalis Pharmaceuticals's helpline number is 212-433-3791
Zentalis Pharmaceuticals's website is zentalis.com
Zentalis Pharmaceuticals's LinkedIn profile is https://www.linkedin.com/company/zentalis-pharmaceuticals
Zentalis Pharmaceuticals has
129 employees.
View email and phone details for 129
employees at Zentalis Pharmaceuticals.
Zentalis Pharmaceuticals's industry is
Biotechnology Research
Zentalis Pharmaceuticals's top competitors are
Acadia Pharmaceuticals Inc.,
Bristol Myers Squibb,
Alnylam Pharmaceuticals,
Cargo Therapeutics,
Crinetics Pharmaceuticals,
Neurocrine Biosciences,
Vertex Pharmaceuticals,
Avidity Biosciences, Inc.,
Mirati Therapeutics,
Poseida Therapeutics, Inc..
Zentalis Pharmaceuticals's support email address is info@zentalis.com
Zentalis Pharmaceuticals's categories are Biotechnology Research
